首页> 美国卫生研究院文献>Molecular Pharmacology >Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding
【2h】

Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding

机译:1型胆囊收缩素受体的高度选择性变构拮抗剂放射性配体的发展及其结合的分子基础的阐明。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Understanding the molecular basis of ligand binding to receptors provides insights useful for rational drug design. This work describes development of a new antagonist radioligand of the type 1 cholecystokinin receptor (CCK1R), (2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinylcarbonyl)amino]-6-methoxy-2-oxo-l-H-indole-3-propanoate (T-0632), and exploration of the molecular basis of its binding. This radioligand bound specifically with high affinity within an allosteric pocket of CCK1R. T-0632 fully inhibited binding and action of CCK at this receptor, while exhibiting no saturable binding to the closely related type 2 cholecystokinin receptor (CCK2R). Chimeric CCK1R/CCK2R constructs were used to explore the molecular basis of T-0632 binding. Exchanging exonic regions revealed the functional importance of CCK1R exon 3, extending from the bottom of transmembrane segment (TM) 3 to the top of TM5, including portions of the intramembranous pocket as well as the second extracellular loop region (ECL2). However, CCK1R mutants in which each residue facing the pocket was changed to that present in CCK2R had no negative impact on T-0632 binding. Extending the chimeric approach to ECL2 established the importance of its C-terminal region, and site-directed mutagenesis of each nonconserved residue in this region revealed the importance of Ser208 at the top of TM5. A molecular model of T-0632-occupied CCK1R was consistent with these experimental determinants, also identifying Met121 in TM3 and Arg336 in TM6 as important. Although these residues are conserved in CCK2R, mutating them had a distinct impact on the two closely related receptors, suggesting differential orientation. This establishes the molecular basis of binding of a highly selective nonpeptidyl allosteric antagonist of CCK1R, illustrating differences in docking that extend beyond determinants attributable to distinct residues lining the intramembranous pocket in the two receptor subtypes.
机译:了解配体与受体结合的分子基础可提供对合理药物设计有用的见解。这项工作描述了1型胆囊收缩素受体(CCK1R),(2-氟苯基)-2,3-二氢-3-[(3-异喹啉基羰基)氨基] -6-甲氧基-2-氧代- lH-吲哚-3-丙酸酯(T-0632),并探索了其结合的分子基础。该放射性配体在CCK1R的变构口袋内以高亲和力特异性结合。 T-0632完全抑制CCK在该受体上的结合和作用,而与紧密相关的2型胆囊收缩素受体(CCK2R)没有饱和结合。嵌合CCK1R / CCK2R构建体被用来探索T-0632结合的分子基础。交换外显子区域揭示了CCK1R外显子3的功能重要性,它从跨膜区段(TM)3的底部延伸到TM5的顶部,包括膜内袋的部分以及第二个细胞外环区(ECL2)。但是,CCK1R突变体(其中面对口袋的每个残基都变成了存在于CCK2R中的残基)对T-0632结合没有负面影响。将嵌合法扩展至ECL2确立了其C端区域的重要性,并且对该区域中每个非保守残基进行定点诱变揭示了TM5顶部Ser 208 的重要性。 T-0632占据的CCK1R的分子模型与这些实验决定因素是一致的,还确定TM3中的Met 121 和TM6中的Arg 336 是重要的。尽管这些残基在CCK2R中保守,但突变它们对两个密切相关的受体有明显的影响,表明方向不同。这建立了CCK1R高度选择性的非肽基变构拮抗剂结合的分子基础,说明了对接的差异超出了决定因素的范围,该决定因素可归因于两种受体亚型的膜内袋内衬的不同残基。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号